Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$15.51 +1.2%	$14.74	$9.57 ▼ $30.41	$2.12B	0.96	1.53 million shs	1.54 million shs
AXSM Axsome Therapeutics	$101.65 +1.0%	$106.72	$72.21 ▼ $139.13	$4.96B	0.48	677,733 shs	638,409 shs
BHC Bausch Health Cos	$6.11 -1.1%	$5.02	$3.96 ▼ $9.85	$2.29B	0.28	2.61 million shs	2.30 million shs
INDV Indivior	$13.95 -0.4%	$11.77	$7.33 ▼ $16.69	$1.93B	0.66	1.11 million shs	1.01 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	+1.24%	-1.21%	+2.51%	+5.30%	-39.18%
AXSM Axsome Therapeutics	+0.95%	-0.04%	-3.25%	-15.55%	+33.07%
BHC Bausch Health Cos	-0.97%	+3.47%	+37.15%	-13.09%	-10.15%
INDV Indivior	-0.43%	-1.62%	+23.89%	+45.62%	-16.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.6032 of 5 stars	3.4	1.0	3.4	2.7	2.5	0.0
AXSM Axsome Therapeutics	4.7172 of 5 stars	4.5	2.0	4.5	2.0	4.2	0.6
BHC Bausch Health Cos	3.6843 of 5 stars	1.9	2.0	4.0	3.9	3.3	0.6
INDV Indivior	2.35 of 5 stars	1.6	5.0	0.0	2.3	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	181.85% Upside
AXSM Axsome Therapeutics	3.06	Buy	$172.33	69.54% Upside
BHC Bausch Health Cos	1.86	Reduce	$7.42	21.39% Upside
INDV Indivior	3.25	Buy	$15.00	7.53% Upside

Current Analyst Ratings Breakdown

Latest AXSM, BHC, ARWR, and INDV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$193.00 ➝ $186.00
6/10/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00
6/9/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$153.00 ➝ $150.00
6/3/2025	AXSM Axsome Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$185.00
5/22/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00 ➝ $180.00
5/20/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/14/2025	AXSM Axsome Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/7/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$200.00 ➝ $180.00
5/6/2025	AXSM Axsome Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$160.00 ➝ $165.00

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$3.55M	603.36	N/A	N/A	$1.54 per share	10.07
AXSM Axsome Therapeutics	$385.69M	12.98	N/A	N/A	$1.18 per share	86.14
BHC Bausch Health Cos	$9.63B	0.23	$7.64 per share	0.80	($0.89) per share	-6.87
INDV Indivior	$1.19B	N/A	$1.81 per share	7.70	($2.52) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	18.02	N/A	-45.33%	-12.49%	8/6/2025 (Estimated)
AXSM Axsome Therapeutics	-$287.22M	-$5.77	N/A	36.05	N/A	-64.39%	-272.80%	-36.69%	8/4/2025 (Estimated)
BHC Bausch Health Cos	-$46M	-$0.11	N/A	1.31	N/A	-0.41%	-540.45%	5.26%	7/30/2025 (Estimated)
INDV Indivior	$2M	-$0.31	N/A	8.16	N/A	-4.02%	-97.29%	15.74%	7/24/2025 (Estimated)

Latest AXSM, BHC, ARWR, and INDV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
4/24/2025	Q1 2025	INDV Indivior	$0.22	$0.41	+$0.19	$0.38	$240.13 million	$266.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	0.31	5.15	5.15
AXSM Axsome Therapeutics	3.48	2.03	1.96
BHC Bausch Health Cos	N/A	1.35	0.97
INDV Indivior	N/A	0.88	0.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
AXSM Axsome Therapeutics	81.49%
BHC Bausch Health Cos	78.65%
INDV Indivior	60.33%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
AXSM Axsome Therapeutics	22.40%
BHC Bausch Health Cos	8.12%
INDV Indivior	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	132.16 million	Optionable
AXSM Axsome Therapeutics	380	49.24 million	38.21 million	Optionable
BHC Bausch Health Cos	20,700	370.08 million	340.03 million	Optionable
INDV Indivior	1,051	N/A	N/A	Not Optionable

AXSM, BHC, ARWR, and INDV Headlines

Recent News About These Companies

Indivior (NASDAQ:INDV) Stock Rating Upgraded by Wall Street Zen

June 22 at 2:15 AM | americanbankingnews.com

Wall Street Zen Upgrades Indivior (NASDAQ:INDV) to Strong-Buy

June 21 at 3:01 AM | marketbeat.com

Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users

June 19, 2025 | prnewswire.com

Promising Cannabis Stocks Worth Watching - June 8th

June 8, 2025 | marketbeat.com

Piper Sandler Keeps Their Buy Rating on Indivior (INDV)

June 8, 2025 | theglobeandmail.com

Top Cannabis Stocks To Keep An Eye On - June 7th

June 7, 2025 | marketbeat.com

Hennion & Walsh Asset Management Inc. Grows Stock Position in Indivior PLC (NASDAQ:INDV)

June 7, 2025 | marketbeat.com

Cannabis Stocks To Consider - June 6th

June 6, 2025 | marketbeat.com

Promising Cannabis Stocks To Follow Today - June 5th

June 5, 2025 | marketbeat.com

Indivior (NASDAQ:INDV) Shares Gap Down - What's Next?

June 3, 2025 | marketbeat.com

Promising Cannabis Stocks To Add to Your Watchlist - June 1st

June 2, 2025 | marketbeat.com

Indivior brings curtain down on turbulent 11-year run in London

June 2, 2025 | proactiveinvestors.co.uk

Indivior to delist from London Stock Exchange, maintain Nasdaq listing

June 2, 2025 | reuters.com

Cannabis Stocks To Add to Your Watchlist - May 31st

June 1, 2025 | marketbeat.com

Indivior (NASDAQ:INDV) Trading 3.8% Higher - What's Next?

May 31, 2025 | marketbeat.com

Man Group plc Grows Holdings in Indivior PLC (NASDAQ:INDV)

May 27, 2025 | marketbeat.com

Investors in Indivior (LON:INDV) have seen solid returns of 156% over the past five years

May 26, 2025 | uk.finance.yahoo.com

Millennium Management LLC Grows Position in Indivior PLC (NASDAQ:INDV)

May 25, 2025 | marketbeat.com

D. E. Shaw & Co. Inc. Takes Position in Indivior PLC (NASDAQ:INDV)

May 25, 2025 | marketbeat.com

Bank of America Corp DE Sells 401,697 Shares of Indivior PLC (NASDAQ:INDV)

May 24, 2025 | marketbeat.com

Indivior PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

April 28, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AXSM, BHC, ARWR, and INDV Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$15.51 +0.19 (+1.24%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$15.89 +0.38 (+2.48%)

As of 04:01 AM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Axsome Therapeutics NASDAQ:AXSM

$101.65 +0.96 (+0.95%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$103.65 +2.00 (+1.97%)

As of 06/23/2025 07:02 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Bausch Health Cos NYSE:BHC

$6.11 -0.07 (-1.13%)

Closing price 06/23/2025 03:59 PM Eastern

Extended Trading

$6.20 +0.09 (+1.47%)

As of 07:00 AM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Indivior NASDAQ:INDV

$13.95 -0.06 (-0.43%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$14.15 +0.20 (+1.43%)

As of 04:39 AM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time